KURA

Kura Oncology, Inc.

Healthcare
Biotechnology
$1.01B market cap

Forecast run · Sep 14, 2026Upside rank 836 of 3,136

Model Signal

ForecastQ Daily Probabilities

48.2%

38.5%

22.3%

Analyst Consensus

Recommendation2.12/5 Buy

Last price$11.39

Price target$23.88

Implied move+109.7%

Analysts17

ForecastQ Portfolios

KURA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.